Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 1/20 | 0.51 |
| ▸ | MDM4 | O15151 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.43 |
| ▸ | CCKAR | P32238 | 2/20 | 0.43 |
| ▸ | CCKBR | P32239 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30917941 | 1.00 | ADAM17 (0.51) | ADAM17MDM4TP53MDM2L3MBTL1 | |
| SCHEMBL5969202 | 1.00 | ADAM17 (0.51) | ADAM17MDM4TP53MDM2L3MBTL1 | |
| SCHEMBL29353403 | 1.00 | ADAM17 (0.51) | ADAM17MDM4TP53MDM2L3MBTL1 | |
| SCHEMBL29364320 | 1.00 | ADAM17 (0.51) | ADAM17MDM4TP53MDM2L3MBTL1 | |
| SCHEMBL1709188 | 1.00 | ADAM17 (0.51) | ADAM17MDM4TP53MDM2L3MBTL1 | |
| SCHEMBL12052757 | 0.93 | L3MBTL1 (0.48) | ADAM17MDM4TP53MDM2L3MBTL1 | |
| SCHEMBL8104292 | 0.93 | L3MBTL1 (0.48) | ADAM17MDM4TP53MDM2L3MBTL1 | |
| SCHEMBL30231797 | 0.93 | ADAM17 (0.51) | ADAM17MDM4TP53MDM2L3MBTL1 | |
| SCHEMBL119657 | 0.92 | MDM4 (0.53) | MDM4TP53MDM2SLC17A5 | |
| SCHEMBL120776 | 0.92 | MDM4 (0.53) | MDM4TP53MDM2SLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698551-A1 | NOVEL SMALL MOLECULE AGONISTS OF INSULIN RECEPTOR (INSR) AS ANTI-DIABETES DRUGS | The University of Hong Kong (CN) | 2026-02-25 | — | — | EP | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| WO-2024217497-A1 | NOVEL SMALL MOLECULE AGONISTS OF INSULIN RECEPTOR (INSR) AS ANTI-DIABETES DRUGS | THE UNIVERSITY OF HONG KONG (CN) | 2024-10-24 | — | — | WO | disclosed |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-23 | — | — | US | disclosed |
| US-20240076311-A1 | METHOD FOR SYNTHESIZING PEPTIDE THIOESTERS AND HEAD-TO-TAIL AMIDE CYCLIC PEPTIDE THEREOF | JIANGSU GENSCRIPT BIOTECH CO., LTD. (CN) | 2024-03-07 | — | — | US | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
| EP-2813512-B1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-03-31 | — | — | EP | disclosed |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-03-04 | — | — | US | disclosed |
| US-9738660-B2 | Selective inhibitors for protein kinases and pharmaceutical composition and use thereof | NATIONAL CHIAO TUNG UNIVERSITY (CN) | 2017-08-22 | — | — | US | disclosed |
| US-20100144648-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-7691852-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| EP-2147925-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2010-01-27 | — | — | EP | disclosed |
| EP-1791837-B1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-20090005419-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-01-01 | — | — | US | disclosed |
| US-7371869-B2 | Substituted hydantoins | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1656390-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2006-05-17 | — | — | EP | disclosed |
| US-20060063814-A1 | Substituted hydantoins | GOODNOW ROBERT A JR | 2006-03-23 | — | — | US | disclosed |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2005-07-14 | — | — | US | disclosed |
| WO-2005000878-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | ADAM17 15/4885MDM4 3559/4885TP53 2654/4885 |
| US-20240076311-A1 | METHOD FOR SYNTHESIZING PEPTIDE THIOESTERS AND HEAD-TO-TAIL AMIDE CYCLIC PEPTIDE THEREOF | VIP, CETP, PITHD1 | ADAM17 1120/4885MDM4 3923/4885TP53 954/4885 |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | ADAM17 15/4885MDM4 3559/4885TP53 2654/4885 |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | ADAM17 15/4885MDM4 3559/4885TP53 2654/4885 |
| US-20090005419-A1 | Organic Compounds | ELAVL1, RBM3, RRBP1 | ADAM17 4511/4885MDM4 982/4885TP53 503/4885 |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | NRDC, NOD2, NGLY1 | ADAM17 141/4885MDM4 2087/4885TP53 2126/4885 |
| US-20060063814-A1 | Substituted hydantoins | HNMT, MAPK6, KYNU | ADAM17 2321/4885MDM4 3878/4885TP53 913/4885 |
| US-20100144648-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | ADAM17 464/4885MDM4 1727/4885TP53 331/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | ADAM17 15/4885MDM4 3559/4885TP53 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.